Deakin University
Browse

Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery

Download (2.14 MB)
Version 3 2024-06-20, 01:11
Version 2 2024-06-03, 06:57
Version 1 2017-10-17, 09:18
journal contribution
posted on 2017-01-01, 00:00 authored by Dongxi Xiang, Sarah ShigdarSarah Shigdar, A G Bean, M Bruce, Wenrong YangWenrong Yang, M Mathesh, Tao Wang, Wang Yin, Phuong TranPhuong Tran, H A Shamaileh, R A Barrero, P Z Zhang, Y Li, Lingxue KongLingxue Kong, K Liu, S F Zhou, Y Hou, A He, Wei DuanWei Duan
Chemotherapy-resistant cancer stem cells (CSCs) are a major obstacle to the effective treatment of many forms of cancer. To overcome CSC chemo-resistance, we developed a novel system by conjugating a CSC-targeting EpCAM aptamer with doxorubicin (Apt-DOX) to eliminate CSCs. Incubation of Apt-DOX with colorectal cancer cells resulted in high concentration and prolonged retention of DOX in the nuclei. Treatment of tumour-bearing xenograft mice with Apt-DOX resulted in at least 3-fold more inhibition of tumour growth and longer survival as well as a 30-fold lower frequency of CSC and a prolonged longer tumourigenic latency compared with those receiving the same dose of free DOX. Our data demonstrate that a CSC-targeting aptamer is able to transform a conventional chemotherapeutic agent into a CSC-killer to overcome drug resistance in solid tumours.

History

Journal

Theranostics

Volume

7

Issue

17

Pagination

4071 - 4086

Publisher

Ivyspring International Publisher

Location

Sydney, N.S.W.

eISSN

1838-7640

Language

eng

Publication classification

C Journal article; C1 Refereed article in a scholarly journal

Copyright notice

2017, Ivyspring International Publisher